HTRF KRAS WT/SOS1 PPI KIT - 500 PTS

HTRF KRAS WT/SOS1 PPI KIT - 500 PTS

分享
品牌: Revvity
pdf 下载产品说明书
pdf 下载SDS
用小程序,查商品更便捷
收藏
对比对比
咨询咨询
    产品介绍
    产品信息

    Overview

    A fast and easy way to identify new inhibitors of KRAS WT / SOS1 protein interactions.KRAS is a small GTPase implicated in various biological processes, such as cell proliferation, cell survival, and cell metabolism. This proto-oncogene is well known to be mutated in many cancer subtypes, inducing an uncontrolled proliferation and cell metabolism modifications. It thereby contributes to the Warburg effect in cancer cells. Like the majority of small GTPase, KRAS binds to GDP in its inactive form or binds to GTP to switch into the active form. KRAS G12C is one of the most commonly represented mutant forms in cancer, which leads to a permanently active state of KRAS. The Ras guanine nucleotide exchange factor, also called SOS1, is a GEF protein promoting the active form of KRAS. The upregulation of the KRAS / SOS1 interaction leads to cancer phenotypes.

    Specifications

    Assay Points
    10000
    Assay Target Type
    Kit
    Assay Technology
    HTRF
    Brand
    HTRF
    Quantity
    1
    Therapeutic Area
    Oncology & Inflammation
    Unit Size
    10,000 Assay Points

    Video gallery

    How it works

    Assay principle

    The KRAS WT/SOS1 PPI assay includes tagged human recombinant partners (KRAS WT and SOS1) and labelled anti-tag reagents for HTRF detection. Without an inhibitor, KRAS WT loaded with GTP binds to SOS1, and the binding of each detection reagent to its tagged target generates an HTRF signal. In the presence of KRAS WT/SOS1 inhibitors or GTP competitors, the HTRF signal decreases.

    ppi-how-it-works-assay-principle-kras-wt-sos1

     

    Assay protocol

    The Human KRAS WT/SOS1 binding assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, compounds or standards are dispensed directly into the assay plate, the pre-mixed GTP and human Tag1-KRAS WT protein is then added together with the human Tag2-SOS1 protein, followed by the dispensing of the HTRF reagents: the anti-Tag2 antibody labeled with Terbium cryptate and the anti-Tag1 antibody labeled with XL665. The reagents labelled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

    ppi-how-it-works-assay-protocol-kras-wt-sos1

     

    Assay validation

    KRAS WT/SOS1 inhibitor screening

    Various compounds known to be KRAS or SOS1 inhibitors were added to the assay. BAY-293, BI-3406, BI-2852, and MRTX-1257 display the right potency and pharmacological ranking, in good correlation with the literature. ARS-1620 and AMG-510, two KRAS G12C selective compounds, had no effect on the assay, confirming that the KRAS WT/SOS1 binding kit is specific to the KRAS WT form.

    assay-validation-human-htrf-kras-wt-sos1_binding-1

     

    Competitive or non competitive nucleotide screening

    The two nucleotides GDP and ATP were added to the assay. GDP, a GTP competitor which is well known to bind KRAS WT, displays the right potency, in good correlation with the literature. ATP, a non GTP competitive nucleotide, had no effect on the assay, confirming the specificity of the kit in detecting GTP competitors or KRAS WT / SOS1 inhibitors.

    assay-validation-human-htrf-kras-wt-sos1_binding-2

     

    声明 :本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。
    货号:
    64KRASWTPEG
    一键复制
    询价
    500Tests
    10000Tests
    选择数量
    当前规格1件起购 
    配送至
    预计4-6周送达,快递: 免运费,若需干冰额外收费